Orforglipron (Foundayo) comes as six tablets: 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg. You start on 0.8 mg once a day, move to 2.5 mg after at least 30 days, then to 5.5 mg after at least 30 more. From there the dose can go up to 9, 14.5 and 17.2 mg, again with at least 30 days on each, if it is needed and tolerated. 17.2 mg is the maximum. It is one tablet a day, at any time, with or without food. There is nothing to mix or measure, so unlike injectable GLP-1s there are no syringe units to work out.

The FDA approved orforglipron as Foundayo (Eli Lilly) on April 1, 2026, for weight management in adults with obesity, or overweight plus a weight-related condition. It is the first GLP-1 medicine that is a small molecule rather than a peptide, which is why it survives the stomach without the fasting rules other GLP-1 pills need.

Foundayo dosage chart

TabletEarliest stepLooks likeImprintSelf-pay price / month
0.8 mgStart (month 1)Pink, roundL / G1$149
2.5 mgMonth 2 or laterLight yellow, roundL / G2$199
5.5 mgMonth 3 or laterGrayish purple, roundL / G3$299
9 mgOptional, month 4+Pink, ovalLilly / G4$299
14.5 mgOptional, month 5+Light yellow, ovalLilly / G5$299*
17.2 mgOptional, month 6+ (maximum)Grayish purple, ovalLilly / G6$299*

“Month 2 or later” means each step comes after at least 30 days on the previous dose. Your prescriber may keep you on a lower dose longer; the label lets the top three steps depend on how you respond and how well you tolerate it. Prices are LillyDirect self-pay prices; *14.5 and 17.2 mg are $299 if you refill within 45 days, otherwise $349. With commercial insurance and Lilly’s savings card it can be as little as $25 a month. Prices change, so check before you order.

Why news stories mention 12 mg and 36 mg

The big trials used an earlier capsule form at 1, 3, 6, 12, 24 and 36 mg. The tablets you can buy are a different formulation, and Lilly states that each capsule dose gives the same blood levels as a smaller tablet dose. So “36 mg orforglipron” in a news story is the same as today’s 17.2 mg tablet, not twice as much.

Capsule dose in trialsSame exposure as tablet
1 mg0.8 mg
3 mg2.5 mg
6 mg5.5 mg
12 mg9 mg
24 mg14.5 mg
36 mg17.2 mg

How much weight people lost at each dose

From the prescribing information, after 72 weeks, counting everyone who started (including people who stopped taking it):

DoseAverage weight changeLost ≥10%Lost ≥15%With type 2 diabetes: average change
Placebo−2.1%13%6%−2.5%
5.5 mg (trial 6 mg)−7.4%32.5%14.3%−5.1%
9 mg (12 mg)−8.3%39.8%20.1%−7%
17.2 mg (36 mg)−11.1%54.5%35.9%−9.6%

Trial doses are shown in brackets. The 11.1% figure is lower than the roughly 12% quoted in some headlines because it includes people who stopped treatment. The results come from adults also following diet and activity advice.

Side effects by dose

As with all GLP-1 drugs, the common side effects are in the gut, and they are why the dose goes up slowly:

Side effectPlacebo5.5 mg9 mg17.2 mg
Nausea10%26%34%35%
Constipation9%20%27%24%
Diarrhea11%21%23%25%
Vomiting4%13%21%24%
Indigestion4%12%16%13%

Other side effects seen in at least 5% of people were stomach pain, headache, bloating, tiredness, burping, reflux and wind. Like other GLP-1 medicines, Foundayo carries a boxed warning about thyroid C-cell tumours seen in rodents, and should not be used by anyone with a personal or family history of medullary thyroid cancer or MEN 2. Lilly notes that orforglipron is not active in rats or mice and did not cause these tumours in them.

Rules on the label

Switching from injections

The label gives no switching schedule, but the ATTAIN-MAINTAIN trial tested exactly this. People who had lost weight over 72 weeks on the highest dose of Wegovy or Zepbound they could tolerate switched straight to daily orforglipron. A year later, the Wegovy group weighed on average 95.9 kg, against 95.0 kg at the switch (+0.9 kg). The Zepbound group went from 90.9 kg to 95.9 kg (+5.0 kg). People switched to placebo regained much more. So orforglipron held most of the loss after semaglutide and part of it after tirzepatide. How to switch is a decision for your prescriber.

Foundayo vs the Wegovy pill

Foundayo (orforglipron)Wegovy pill (oral semaglutide)
What it isSmall molecule, not a peptidePeptide with an absorption enhancer
Strengths0.8, 2.5, 5.5, 9, 14.5, 17.2 mg1.5, 4, 9, 25 mg
StepsEvery 30+ days; top three steps optionalEvery 30 days up to 25 mg
How to takeAny time, with or without food or waterMorning, empty stomach, up to 4 oz (120 mL) of water, then wait 30 minutes

The two pills have not been compared head to head in a trial, so their weight-loss figures cannot be lined up fairly. The practical difference is the routine: Foundayo has no timing rules. For the injectable options, see our GLP-1 dosage chart.

Storage

Foundayo comes in bottles of 30 tablets with a desiccant. Keep it at room temperature, 20–25 °C (68–77 °F); short spells between 15 and 30 °C (59–86 °F) are fine. It does not need the fridge.

Where things stand (November 2026)

Is there an orforglipron calculator?

For the tablets, no calculation is needed: the strength is printed on the bottle. Our orforglipron calculator exists because orforglipron is also sold online as “research” powder. That powder is not checked by any regulator, its strength and purity are unknown, and it is not Foundayo. If you are comparing it with injectable drugs, the semaglutide and tirzepatide charts show those doses in syringe units.

Sources: Foundayo prescribing information (dosing, results, side effects, storage); Lilly Medical: capsule vs tablet doses; LillyDirect prices; Lilly: ATTAIN-MAINTAIN results; EMA: Foundayo opinion; Lilly: sleep apnoea results.